Artiva Biotherapeutics to Present New Data at Major 2026 Cell Therapy Conference

San Diego, California — January 21, 2026 — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company dedicated to developing effective, safe and accessible cell therapies for patients with autoimmune diseases and cancers, today confirmed its participation in the upcoming 2026 Transplantation & Cellular Therapy Meetings (also known as the Tandem Meetings) of ASTCT® and CIBMTR®. The event will be held February 4–7, 2026, in Salt Lake City, Utah, bringing together scientific and clinical experts in transplantation, immunotherapy and cellular therapy.

Focus on AlloNK®: Cost-Effectiveness and Clinical Durability

Artiva’s presentations at the Tandem Meetings will showcase new data on its lead cell therapy program, AlloNK® (also known as AB-101), an off-the-shelf natural killer (NK) cell therapy. These poster presentations emphasize two key areas of interest:

1. Cost-Effectiveness of AlloNK in Community Rheumatology Settings

A poster titled “AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases” will be featured during the Health Services and Barriers to Access session on Thursday, February 5, 2026, at 6:30 pm MST. The analysis highlights how AlloNK could offer a more affordable immunotherapy option compared to CAR-T therapies when used in community-based rheumatology practices — potentially expanding access to advanced cell therapies outside specialized hospital centers.

The poster is authored by Nicholas Veomett, Ph.D., Vice President of Corporate Development at Artiva. It provides insights into real-world utilization of AlloNK in outpatient clinical environments and suggests meaningful reductions in treatment costs and barriers to patient access.

2. Durability of AlloNK in Non-Hodgkin Lymphoma (NHL)

Another presentation, titled “A Multi-Center, Phase 1/2 Trial of AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma,” will be shown in the Lymphoma – Clinical session at the same date and time. This poster discusses long-term data from a multi-center Phase 1/2 clinical trial evaluating the performance of AlloNK with or without the monoclonal antibody rituximab in patients with relapsed or refractory NHL.

The presentation is authored by Umer Farooq, M.D., Clinical Professor of Internal Medicine-Hematology, Oncology and Blood & Marrow Transplantation at the University of Iowa, and highlights sustained anti-tumor activity observed in study participants.

About the 2026 Transplantation & Cellular Therapy Meetings

The Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are global scientific conferences that bring researchers, clinicians and experts together to present the latest advancements in hematopoietic cell transplantation (HCT), cellular immunotherapy and related clinical science. Scheduled for February 4–7, 2026, in Salt Lake City, this year’s event includes plenary sessions, concurrent scientific presentations, educational workshops, poster sessions, and networking opportunities for professionals focused on improving patient outcomes through cutting-edge therapies.

About Artiva Biotherapeutics and AlloNK®

Artiva Biotherapeutics is a clinical-stage biotech firm headquartered in San Diego, California, focused on developing cell therapies designed to treat serious autoimmune conditions and cancers. Its flagship program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy engineered to enhance antibody-dependent cellular cytotoxicity and support targeted immune responses.

AlloNK is currently being assessed in multiple clinical trials, including a company-sponsored basket trial for autoimmune diseases like rheumatoid arthritis and Sjögren’s disease, as well as investigator-initiated trials in other B-cell driven immune disorders. Artiva’s broader pipeline also includes CAR-NK candidates directed against various cancer targets.

The company was established in 2019 through a strategic partnership that granted Artiva exclusive global rights (outside Asia, Australia, and New Zealand) to NK cell manufacturing technology from GC Cell (formerly GC Lab Cell Corporation), a healthcare firm based in South Korea.

For more details about Artiva’s presentations and research programs, attendees and interested readers are encouraged to visit the official Tandem Meetings website or Artiva’s corporate site at www.artivabio.com.